Brian Fuehrlein

Dr. Brian Fuehrlein

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
YLYu Kyung Lee
Yu Kyung Lee
MGMark S. Gold
Mark S. Gold
KBKenneth Blum
Kenneth Blum
PTPanayotis K. Thanos
Panayotis K. Thanos
CHColin Hanna
Colin Hanna
BFBrian Fuehrlein
Brian Fuehrlein
Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.

18 April 2018 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
BFBrian Fuehrlein
Brian Fuehrlein
LKLorig K Kachadourian
Lorig K Kachadourian
EDElizabeth K. DeVylder
Elizabeth K. DeVylder
LTLouis A. Trevisan
Louis A. Trevisan
Marc PotenzaMarc Potenza
Marc Potenza
RPRobert H. Pietrzak
Robert H. Pietrzak

20 March 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MCMuhammet Celik
Muhammet Celik
MGMark Gold
Mark Gold
BFBrian Fuehrlein
Brian Fuehrlein
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research.

1 January 2022 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
YLYu Kyung Lee
Yu Kyung Lee
MGMark Gold
Mark Gold
BFBrian Fuehrlein
Brian Fuehrlein

5 December 2023 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
MEMohamed Elmarasi
Mohamed Elmarasi
BFBrian Fuehrlein
Brian Fuehrlein
Major depressive disorder (MDD) is a serious mental health condition that contributes to health complications, financial burden and death. In 2020, about one in five US adults had a lifetime diagnosis of MDD. With Major Depressive Disorder (MDD) being a common mental health concern, it is important to understand treatment patterns within public health systems like Medicaid, as they play a crucial role in providing care to diverse populations. The study investigated antidepressant usage and market distribution in the Medicaid Program. By doing so, the study aimed to provide insights into how these trends reflect broader changes in mental health treatment practices and policy implications within the Medicaid system during the study period. Public Medicaid data from 2017 to 2021 were analyzed, focusing on 30 FDA-approved antidepressants. Spending and prescription data were aggregated using Excel and Python. The total US Medicaid expenditure on antidepressants increased from about $1 billion dollars in 2017 to $1.12 billion dollars in 2021, an increase of about 10%. Consistently, SSRIs were the class of antidepressants that Medicaid spent the most on. The highest Medicaid spending on a single antidepressant in 2017 and 2018 was bupropion. During the remaining years of the study (2019, 2020, 2021) Medicaid appropriated most funds toward Vortioxetine. The total number of antidepressant prescriptions increased from 52 million scripts to 59 million scripts (an increase of about 14%). The increase in Medicaid spending on antidepressants during the study period can be explained by an increase in utilization (a 14% increase in antidepressant prescriptions from 2017 to 2021), and a shift toward prescribing newer more costly antidepressants (like SSRIs and others) and away from prescribing older, less costly antidepressants like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs).”

30 January 2021 in Community Mental Health Journal
Verified
Journal Article
Closed access
PDF file
LMLorena Mitchell
Lorena Mitchell
BFBrian Fuehrlein
Brian Fuehrlein